Publikationen in Zusammenarbeit mit Forschern von Kyoto University (27)

2024

  1. Correction to: Optical coherence tomography in coronary atherosclerosis assessment and intervention (Nature Reviews Cardiology, (2022), 19, 10, (684-703), 10.1038/s41569-022-00687-9)

    Nature Reviews Cardiology

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial

    The Lancet Oncology, Vol. 24, Núm. 1, pp. 77-90

  3. Machine learning to predict major bleeding during anticoagulation for venous thromboembolism: possibilities and limitations

    British Journal of Haematology, Vol. 201, Núm. 5, pp. 971-981

2022

  1. Cost-effectiveness of palbociclib in early breast cancer patients with a high risk of relapse: Results from the PENELOPE-B trial

    Frontiers in Oncology, Vol. 12

  2. Effects of capecitabine as part of neo-/adjuvant chemotherapy – A meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patients

    European Journal of Cancer, Vol. 166, pp. 185-201

  3. Novel genes and sex differences in COVID-19 severity

    Human molecular genetics, Vol. 31, Núm. 22, pp. 3789-3806

  4. Optical coherence tomography in coronary atherosclerosis assessment and intervention

    Nature Reviews Cardiology, Vol. 19, Núm. 10, pp. 684-703

2021

  1. Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 39, Núm. 14, pp. 1518-1530

  2. Spontaneous ARIA-like events in cerebral amyloid angiopathy–related inflammation a multicenter prospective longitudinal cohort study

    Neurology, Vol. 97, Núm. 18, pp. E1809-E1822

  3. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

    npj Breast Cancer, Vol. 7, Núm. 1

2020

  1. Derivation and validation of a clinical prediction rule for thrombolysis-associated major bleeding in patients with acute pulmonary embolism: The BACS score

    European Respiratory Journal, Vol. 56, Núm. 6

  2. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

    The Lancet Oncology, Vol. 21, Núm. 12, pp. 1574-1588

  3. Health-Related Quality of Life in MONARCH 3: Abemaciclib plus an Aromatase Inhibitor as Initial Therapy in HR+, HER2− Advanced Breast Cancer

    Oncologist, Vol. 25, Núm. 9, pp. e1346-e1354

2019

  1. Correction to: Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer (BMC Cancer (2019) 19 (517) DOI: 10.1186/s12885-019-5687-0)

    BMC Cancer

  2. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer

    npj Breast Cancer, Vol. 5, Núm. 1

  3. Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer

    BMC Cancer, Vol. 19, Núm. 1

  4. Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2–positive advanced breast cancer: Final results from MARIANNE

    Cancer, Vol. 125, Núm. 22, pp. 3974-3984

2018

  1. Reply to 'the St Gallen international expert consensus on the primary therapy of early breast cancer 2017: Te point of view of an international panel of experts in radiation oncology' by Kirova et al.

    Annals of Oncology

2017

  1. De-escalating and escalating treatments for early-stage breast cancer: The St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017

    Annals of Oncology, Vol. 28, Núm. 8, pp. 1700-1712